^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

INTEGRATIVE APPROACH TO FIND PREDICTIVE MARKERS OF RESPONSE TO DARATUMUMAB IN MULTIPLE MYELOMA

Published date:
05/12/2021
Excerpt:
We retrospectively included 97 multiple myeloma patients treated with Dara...Maxstat analysis of CD200 expression found that an expression of this protein in more than 95% of plasma cells was significantly associated with the absence of response to Dara (Figure).